$5.17
$145.31
52-Week Range
At a Glance
AI-generatedAbivax SA, a clinical-stage biotech focused on obefazimod for IBD, reported a net loss of €336.1 million for FY 2025, up 91% YoY from €176.2 million in 2024 and €147.7 million in 2023, driven by intensified R&D spending on Phase 3 UC trials and Phase 2b CD trial.
$7.8B
Market Cap
$7M
Revenue
-$215M
Net Income
Employees69
Fundamentals
How The Business Makes Money
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
Industry Biotechnology
Activity
What Changed Recently
Company Profile
CIK0001956827
ISINUS00370M1036
CUSIP00370M103
Phone33 1 53 83 08 41
Address5, rue de la Baume, Paris, 75008, FR
SEC EDGAR